AstraZeneca And Huma On Digital’s Value For Pharma
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.
You may also be interested in...
Cordio Medical Is Using Patients’ Voices To Spot Heart Failure
As fluid builds up in the lungs, the “engine” of a patient’s voice is smothered. Medtech Insight spoke to Cordio Medical’s CEO about how the company’s smartphone-based software could warn clinicians almost three weeks in advance of decompensation.
Podcast: OxSonics Hopes To Use Ultrasound To Enhance Drug Efficacy – Without Reformulation
In this one-off podcast, reporter Barnaby Pickering speaks Jérôme Marzinski and Dr Christian Coviello, the CEO and CTO, respectively, of OxSonics, a UK-based start-up which is working on an ultrasound-based technology that has been designed to enhance the potency of oncological drugs.
Speaking To AstraZeneca And Huma About Digital’s Value For Pharma
AstraZeneca has been working with Huma to develop a series of software-based tools for monitoring patients. Medtech Insight spoke to both companies about the value of these partnerships and the potential challenges.